BestStartup.co.uk is a proud supporter of British business. If you are an investor or looking for a British supplier of exceptional quality offerings this list can provide you with a great starting point.
This article showcases our top picks for the best Nottingham based Biotechnology companies. These startups and companies are taking a variety of approaches to innovating the Biotechnology industry, but are all exceptional companies well worth a follow.
We tried to pick companies across the size spectrum from cutting edge startups to established brands.
We selected these startups and companies for exceptional performance in one of these categories:
- Innovative ideas
- Innovative route to market
- Innovative product
- Exceptional growth
- Exceptional growth strategy
- Societal impact
Top Nottingham Biotechnology Companies
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England.
The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr.
Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian.
As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No.
7,402,403 and No. 7205117.
Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials.
Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.. .
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma.
Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham..
Exco InTouch focuses on the development of digital engagement and data capture solutions for clinical research and healthcare programs. Exco InTouch offers Gather, a system that enables clinical research providers gain data and improve patient engagement.
The company also develops solutions that focus on patients’ long term condition management. Exco InTouch was founded in 2004 by Tim Davis.
It is headquartered in Nottingham, England.. .
Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots.
The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients..
Critical Pharmaceuticals is a biotechnology company with proprietary drug delivery technologies for the sustained release and nasal delivery of proteins and peptides and labile or insoluble small molecules. Critical Pharmaceuticals was founded by Professor Steve Howdle in 2002 based on his research into supercritical fluids.
When gases reach a certain temperature and pressure (the critical point) they become “supercritical” and take on both gas and liquid like properties. He noticed that supercritical carbon dioxide (scCO2) was able to penetrate certain polymers, and in a moment of inspiration realised that this could be used to mix thermally labile or solvent sensitive substances into the polymers..
Tumour Trace is dedicated to developing innovative, patented cancer screening, and diagnostic technology. Based on peer review research, their in- vitro portable screening device has been validated following proof of concepts in the UK, Serbia and India.
Their vision is to enable screening covering all cancers to be available to everyone, everywhere.. .
Sygnature Discovery is an independent provider of integrated drug discovery resource and expertise. It undertakes hit identification, hit-to-lead and lead optimization projects, and complete drug discovery programs.
Core capabilities include medicinal chemistry, in vitro bioscience, computational sciences and informatics, DMPK/physical sciences, and project management. Sygnature operates from state of the art facilities in Nottingham and employs over 200 staff, most of whom are PhD scientists..
Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. They partner with excellence to improve therapies for people with serious diseases.
They are proud to be recognized as the world leader in with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 80 people all committed to improving patient quality of life.
They are just as passionate about albumin and albumin-enabled therapies today as They were when they started 30 years ago.. .
Source Bioscience provides laboratory services and products to the healthcare and clinical, life science research and biopharma industries. Services include diagnostic testing for cancer and other infectious disease, DNA sequencing and contract research activities, cryostorage and stability testing.
Products include serology products for blood and tissue banking, life science research reagents and controlled environment chambers.. .
Orthogem develops and manufactures synthetic bone grafts. Its patented Tripore technology platform has enabled the creation of a pipeline of SBG’s formulated for a variety of clinical applications, ranging from spinal to oral cranial facial surgery.
Orthogem’s products include TriPore Granules, TriPore MPA, and TriPore Blocks. Wei Lo founded it in 2001, with its headquarters in Nottingham in the United Kingdom..
Maetrics is a full service life sciences consulting firm. Founded in 1984, Maetrics has evolved to become a global force supporting a significant number of medical device, pharmaceutical, diagnostics, and biotech firms with their most critical quality, regulatory, and compliance challenges.
The company is exclusively focused on the life science industry, enabling us to provide superior insights to our clients. Their unique business acumen and delivery model has been rewarded by repeated engagements with our client base year after year..
CellAura Technologies is the home of innovative screening products for the drug discovery industry. CellAura is a spin-out company from the University of Nottingham.
Combining world-renowned expertise in the fields of synthetic chemistry and molecular pharmacology, CellAura produces high-quality fluorescent G-protein coupled receptor ligands for use in molecular pharmacology and imaging at the single cell level.. .
Founded in 1997, we provide pharmaceutical development, clinical trial manufacturing, advanced analysis and consulting services for the pharmaceutical industry worldwide. Our unique resource can flexibly link early formulation development to clinical trial manufacture.
The added advantage of a world renowned materials characterisation service, ensures rapid understanding of drug substance, process and formulation issues.. .
Serascience Limited is a specialist cancer diagnostic company established in April 2011 to develop medical devices for the diagnosis and management of patients with myeloma and related disorders, collectively known as B-cell dyscrasias. Our innovative products will improve patient management through better diagnostic and prognostic assessment.
Serascience supply a broad range of class and subclass specific anti immunoglobulin antibodies, for research use. We offer unique, highly specific, quality antibodies at a competitive price.
Our catalogue includes monoclonal antibodies for all immunoglobulins classes, and a number of subclasses, as well as antibodies to the heavy and light chains of immunoglobulins. These antibodies can be used for an array of applications and assays, such as WB (Western blots), ELISAs (Enzyme-linked immunosorbent assays), IP (Immuneprecipitation), IHC (Immunohistochemistry), ICC (Immunocytochemistry), and flow cytometry..
You may write to us at: BestStartup.co.uk/Fupping Ltd, 349 Royal College Street, London, England, NW1 9QS.